Though Paul Ehrlich first hypothesized the theory of cancer immune surveillance in 1909, the hypothesis gained no real traction for almost a century because of the lack of supporting evidence. Over the last several decades, however, the established link between immunosuppression and tumorigenic viruses in patients with human immunodeficiency virus infection has renewed support for the role of immune surveillance in the containment of neoplasms. 1 These observations have been further underscored by the increased incidence of malignancies in solid organ transplant patients on chronic immunosuppression. However, an infectious etiology has not yet been identified in some of these post-transplant secondary malignancies, 2 suggesting that tumor immunity might not be restricted to neoplasms, which develop secondary to infection by a foreign pathogen. Chronic lymphocytic leukemia (CLL), the most prevalent of the adult leukemias, is one such malignancy for which an infectious etiology is not suspected. Nonetheless, there is much evidence that the immune system can be induced to recognize CLL, including the existence of a graft versus leukemia effect after allogeneic hematopoietic stem cell transplantation, the documentation of a disease-specific antigenic profile, and the demonstration of de novo immune responses following experimental vaccination protocols. [3] [4] [5] In this study, we demonstrate that CLL patients with advanced disease exhibit bias toward homozygosity at human leukocyte antigen (HLA) loci, limiting the diversity of antigen presentation and potentially providing the nascent tumor with an advantage in the process of immune escape. This is the first report to correlate the clinical progression of CLL with HLA homozygosity, demonstrating that immune surveillance might have a role in the containment of non-infectious neoplasms.
To study the effects of HLA homozygosity and allelic variation on progression of CLL, we examined the medical records of all patients with advanced CLL who proceeded to transplant (249 total) and hence for whom HLA typing was available (clinical characteristics of these patients outlined in Table 1 ). Patient HLA allele frequencies were determined and compared with those of a control population of 747 race-matched healthy controls identified sequentially in the MD Anderson umbilical cord blood bank database. Among this group of CLL patients, 14.0% of HLA-A, -B, -C and -DR alleles were homozygous in comparison with 11.9% of HLA alleles among the population at large (Table 2 ). This significant (Po0.04) difference corresponded to an odds ratio (OR) for homozygosity of 1.20 (95% confidence interval (CI) ¼ 0.97-1.48). The patient data set was not large enough to discern individual differences at HLA-A, HLA-B or HLA-DR; however, the odds ratio for patients who were homozygous at HLA-C was highly significant (21.7 versus 14.6%, P ¼ 0.002; OR ¼ 1.62, 95% CI ¼ 1.13-2.33). Patients homozygous at more than one HLA locus were highly overrepresented as well (12.0 versus 7.5%, P ¼ 0.006; OR ¼ 1.69, 95% CI ¼ 1.06-2.70).
We then analyzed the HLA alleles present in both the control and CLL populations, identifying a number of specific alleles that were overrepresented in the CLL population as a whole (Table 3) À7 ). Given that the OR for the HLA-A1/B8/C7 haplotype was significantly higher than that of any individual allele, it is likely that the presence of two or more of these three alleles contributed independent degrees of risk.
If HLA homozygosity and/or haplotype bias truly have a genuine biological effect on disease progression, we reasoned it should be possible to correlate HLA variables with the clinical course of disease by independent statistical methods. In addition, we also identified a number of other HLA-dependent factors (that is, Tables 2 and 3) that might be involved in CLL, several of which might have a more prominent effect than HLA homozygosity upon disease progression. To account for potentially confounding variables, we compared HLA-A1 þ patients and patients without any detrimental allelic combinations ( Figure 1a and Table 4 ). A similar analysis comparing HLA-
À individuals demonstrated the significant, independent contribution of HLA-C7 in combination with HLA-A1 (13.9 versus 31.8 months; P ¼ 0.0008, Figure 1b and Table 4 ). Analysis of patients possessing only HLA-C7 as a risk factor demonstrated the proper trend toward decreased PFS but was not quite statistically significant (P ¼ 0.07, data not shown). Independent analysis of HLA-B8 could not be performed because of the tight selective association of HLA-B8 and HLA-C7 and an absence of any B8 þ C7 À individuals. After controlling for HLA-A1/B8/C7, we compared disease progression of individuals homozygous at one or more HLA-A, -B, -C, or -DR loci to individuals heterozygous at all loci within our patient population. As demonstrated by Figure 1c , median PFS was 25.7 months among individuals homozygous at one or more HLA locus versus 31.8 months among HLA heterozygotes (P ¼ 0.007, Figure 1c and Table 4 ). Further, essentially all individuals homozygous at an HLA locus reached first progression within 5 years of initial treatment, whereas 26% of the heterozygotes did not. Individual Kaplan-Meier analysis of each HLA locus demonstrated that homozygosity at any locus seemed to have an effect on disease progression; however, there were not enough data points to reach statistical significance for any individual HLA locus.
Although it might be argued that observed differences in PFS could be because of the differences in the original treatment regimen of each patient, such an argument would be dependent on the concordant stratification of HLA differences among specific treatment regimens. Accordingly, we confirmed that distribution of HLA-A1, HLA-B8, HLA-C7 and HLA homozygosity were statistically identical among patients who received fludarabine-based initial treatment regimens (73.5% of patients) and patients who did not receive fludarabine-based initial treatment regimens (data not shown). Further, though our data might appear to suggest that allogeneic transplantation is not curative for CLL in the absence of appropriate HLA determinatives, we do not by any means draw this conclusion. These data were derived from all patients in the transplant database between 1990 and 2008, and a majority of these patients did not benefit from the latest advances in transplant technology including optimized conditioning regimens, the advent of rituximab, and routine immunological intervention with techniques such as donor lymphocyte infusion. 6 Moreover, allotransplantation was not the initial treatment regimen for the vast majority of these patients.
Diversity of antigen presentation by the major histocompatibility complex is constrained in a haplotype-and allele-specific manner. Statistically, the more diversity among HLA loci, the more likely it should be that a high affinity, immunogenic epitope will be presented. Conversely, a less varied HLA phenotype is less likely to present such an epitope. For these reasons the mammalian major histocompatibility complex antigen presentation machinery has evolved a highly diverse and polymorphic repertoire of HLA loci that is able to present, in total, an extremely broad array of epitopes. Numerous infectious disease studies [7] [8] [9] have demonstrated significant negative clinical consequences of HLA homozygosity as well as positive consequences of HLA heterozygosity on development of disease and clinical outcome. This same paradigm should also hold true for non-infectious neoplasms, provided that the immune system is capable of recognizing and eradicating cancerous cells based on the antigenic repertoire that differentiates neoplastic self from non-neoplastic self. Our data demonstrates that patients with advanced CLL, a disease for which there is no known infectious component, are significantly more likely than a large, race-matched control population to express HLA-A1, HLA-B8 and HLA-C7. Although only HLA-A1 retained statistical significance following Bonferoni correction, the highly significant frequency at which all three alleles were found together among advanced CLL patients (OR ¼ 2.15, Po10
À7
) suggests that each allele imparts an independent degree of risk. Several other studies have attempted to identify an overrepresentation of specific HLA alleles among CLL populations. 10, 11 Most significant to the present work, HojjatFarsangi et al. 11 reported an overrepresentation of HLA-DR7 among a cohort of 87 Iranian CLL patients. Though we also observed an increased expression of HLA-DR7 in our CLL patient population versus the control population (16.5 versus 13.2%, Po0.04), Kaplan-Meier analysis did not identify any significant differences in PFS for CLL patients with this allele versus those without (data not shown). On the basis of these results, it might be hypothesized that the overrepresentation of HLA-DR7 might be because of the selective associative effects between HLA-D7 and one or more of the HLA class I alleles that we were able to identify. Indeed, among the normal controls, HLA-D7 was associated with 16.9% of individuals possessing the HLA-A1/B8/C7 haplotype versus 13.2% of the control population as a whole (data not shown). In summary, the data indicate that immune surveillance may have a relatively significant role in the control of CLL given the prevalence of specific major histocompatibility complex class I alleles and the potential effect of HLA homozygosities on disease progression.
There are several limitations of this study. One issue of obvious concern is selection bias. Ideally, we would identify a large sample of newly diagnosed CLL patients, perform HLA Letters to the Editor typing and follow their disease course. As many patients with CLL are not HLA typed on initial presentation, our sample of CLL patients was comprised principally of individuals with advanced disease or poor prognosis who were being prepared for hematopoietic stem cell transplantation. Because of this, somewhat confounding caveat, we cannot determine with any degree of certainty that HLA phenotype and immune surveillance have a role in the initiation of CLL and cannot rule out the possibility that CLL develops in an HLA-independent manner, after which time HLA homozygosity becomes a factor in determining the course of disease progression. Thus, our results require prospective validation. In addition, whereas it would have been ideal to stratify patients by race, too few CLL patients were of non-Caucasian origin for any meaningful analysis. Finally, we are unable to comment on any interaction between HLA alleles and other known prognostic factors (chromosomal deletions, immunoglobulin gene somatic hypermutation, ZAP-70 status), as many of the patients in this study did not have this data available upon initial presentation.
In conclusion, we show that the disease progression in CLL may be influenced by both HLA homozygosity and haplotype bias, suggesting that the CLL progression is controlled to some degree by immune surveillance. If validated prospectively, these findings could have significant implications for the prognostic value of HLA alleles. More strikingly, these data are the first to demonstrate that progression of a cancer without a known infectious component could be controlled by the immune system, and observation that could have significant effect on the future development of immune-based therapies. Over the last several years, molecular analyses in acute myeloid leukemia (AML) have established clinical-pathological and prognostic correlations that have better defined subgroups in this heterogeneous disease and influenced risk-adapted therapeutic approaches on recent clinical trials. Genetic markers such as FLT3 internal tandem duplications (FLT3-ITD), were first identified in adults 1 and subsequently in children, 2 as conferring a poor prognosis. By contrast, mutations in nucleophosmin (NPM1) 3, 4 and more recently, CCAAT/enhancer-binding protein alpha (CEBPA) 5 have been found to be associated with improved outcomes in both adult and pediatric studies. However, despite being initially described almost 20 years ago, the prognostic implications of mutations involving the RAS proto-oncogenes, remain controversial. 6 The RAS gene family is comprised of three homologues, HRAS (11p15.5), KRAS (12p12.1) and NRAS (1p13.2), all of which function as membrane-associated guanosine nucleotide phosphate-binding proteins. 7 Mutations in RAS genes are frequent in AML and serve as prototypic Class I lesions, initiating key downstream hyperproliferative signal transduction pathways. 8 NRAS mutations (NRASmut) are the most common, occurring in 10-20% of AML patients. RAS mutations have been linked to leukemic progression in myelodysplastic syndrome and an inferior outcome in AML by some researchers; 9-13 whereas other studies have reported no survival difference in AML patients harboring RAS mutations compared with those without RAS mutations.
14,15 Still other reports have suggested the presence of a RAS mutation may actually improve survival and/or response to therapy. 15 Here, we report on the incidence and prognostic significance of NRASmut in a large cohort of children with AML who were treated on two recent cooperative group studies.
Of the 1241 eligible patients with de novo AML enrolled on CCG-2961 and COG-AAML03P1, diagnostic DNA was available for 825 children. Demographics, laboratory and clinical characteristics, and outcome for patients with and without available specimens were comparable to the study population at large, as reviewed in previous studies. 7 KRAS mutations were examined for 183 patients treated on CCG-2961, and only two mutations were identified, so no further analysis was conducted. HRAS mutations are rare in AML, 15 and thus not examined in this study (data not shown). Exons 1 and 2 of the NRAS gene were amplified, sequenced and evaluated for genomic alterations. Of the 825 specimens tested, 86 (10%) had a missense mutation in the amplified coding region. Mutations involved either codon 12 (n ¼ 52, 60%) or 13 (n ¼ 33, 38%), as have been previously described, with one unique mutation in codon 29. No mutations were identified in codon 61, a third codon previously reported to be involved in adult AML (Supplementary Table 1) . 16 In order to establish the somatic, disease-associated nature of these mutations, DNA extracted from remission specimens available from 12 patients with NRASmuts was evaluated for the presence of NRASmuts. We failed to demonstrate the presence of NRASmuts in the remission specimens, demonstrating that the NRASmuts were diseaseassociated mutations and not germline polymorphisms. Sex, age, and race were comparable between NRASmut positive and wild-type patients. Similarly, there was no difference in frequency of organomegaly or extramedullary disease (central nervous system involvement or chloroma). Median diagnostic WBC (28.9 Â 10 3 /ml vs 21.6 Â 10 3 /ml, P ¼ 0.19) and platelet counts (45 Â 10 3 /ml vs 48 Â 10 3 /ml, P ¼ 0.97) at diagnosis were also similar between the two cohorts. Diagnostic bone marrow blast counts were lower in patients with NRASmut than in those without the mutation (64% vs 71%, P ¼ 0.05) (Supplementary Table 1 ). NRAS mutational status was correlated with the French-American-British Classification of AML subtypes 17 for
